Core Insights - Viridien has launched the Sercel Accel, the first onshore drop node solution aimed at transforming land seismic data acquisition [1][5] - The Accel solution significantly reduces deployment time and labor requirements, enhancing operational efficiency and reducing costs by up to 30% [2][5] Product Features - Accel eliminates the need for nodes to be buried or planted, streamlining logistics and improving in-field agility [2] - The solution is powered by the Sercel QuietSeis MEMS sensor, ensuring total data integrity and reliability [3] - Accel includes modular Solution Packs that combine nodes, software, and services, allowing customization based on project needs [4] Company Overview - Viridien is a technology and Earth data company focused on sustainable solutions for natural resources and infrastructure challenges, employing around 3,400 people globally [6]

Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission File Number: 001-39811 Dogwood Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other juris ...

Exhibit 99.1 Dogwood Therapeutics Announces First Quarter 2025 Financial Results - Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Study - - Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b study interim data readout is expected in Q4 2025 - - Cash on hand of $17.5M provides operational runway through Q1 2026 - ATLANTA, Ga., May 8, 2025 -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the "Company"), a development-stage biotechno ...

Core Insights - Viridien has sold its Sercel Marlin™ Offshore Logistics management solution to Oil and Natural Gas Corporation (ONGC) to improve operational efficiency and safety in ONGC's Western offshore exploration and production (E&P) operations in India [1][2] - The deal includes a five-year contract for dedicated on-premises software and support services, which will enhance ONGC's logistics through real-time vessel tracking and improved operational planning [1][2] - The integration of advanced AI and machine learning algorithms in the Sercel Marlin solution aims to future-proof ONGC's operations and support its carbon neutrality objectives [2][3] Company Overview - Viridien is a technology and digital company focused on Earth data, aiming to resolve complex challenges in natural resources, energy transition, and infrastructure [4] - The company employs approximately 3,400 people globally and is listed on Euronext Paris SA under the ticker VIRI [4]

Combined General Meeting and Board of Directors Meeting of April 30, 2025 Paris, France – April 30, 2025 The Combined General Meeting of Viridien, chaired by Mr. Philippe SALLE was held on April 30, 2025 in Paris. The voting results and video replay of the event will be available on the Company’s website at the following address: https://www.viridiengroup.com/investors/shareholders/general-meetings. The General Meeting approved all resolutions that were submitted to it and notably: The statutory financia ...

Core Insights - The company achieved significant milestones in Q1 2025, including the termination of a vessel capacity agreement and successful bond refinancing, enhancing operational flexibility and cash generation [3][4][5] - Financial results for Q1 2025 showed a revenue increase of 10% to $301 million and a 35% rise in adjusted EBITDA to $143 million, indicating robust business performance [2][5][9] - The company anticipates generating approximately $100 million in net cash flow for the year, assuming moderate fluctuations in the oil market [4][10] Financial Performance - Q1 2025 revenue reached $301 million, a 10% increase from the previous year, driven by growth in Geoscience and Earth Data segments [2][9] - Adjusted EBITDA for Q1 2025 was $143 million, reflecting a 35% increase, supported by revenue growth and cost reductions [2][5][9] - Net cash flow for Q1 2025 was $(20) million, compared to $30 million in the same period last year, impacted by a $42 million interest payment [2][5][12] Segment Performance - Digital, Data, and Energy Transition (DDE) segment revenue increased by 16% to $214 million, with Geoscience growing by 25% and Earth Data by 7% [5][9] - Sensing and Monitoring (SMO) segment revenue was nearly stable at $87 million, with adjusted EBITDA rising by 37% due to cost reductions [5][9] - The company reported a backlog in Geoscience of $329 million, a 45% increase year-over-year, indicating strong future demand [11] Debt and Liquidity - The company successfully refinanced $447 million and €578 million notes, replacing them with $450 million and €475 million senior secured notes due in October 2030 [5][10] - Net debt stood at $974 million, with liquidity at $257 million, reflecting a focus on cash flow generation and deleveraging [5][11] Future Outlook - The company expects continued growth in Geoscience supported by advanced technology and a strong backlog, alongside improved cash EBITDA in Earth Data following the end of vessel commitment penalty fees [10] - The restructuring plan in Sensing & Monitoring is anticipated to yield further savings, contributing positively to overall profitability [10]

Viridien Société anonyme with a share capital of € 7,161,465 Registered office : 27 avenue Carnot, 91300 Massy, France Evry Trade and Company Register No. 969 202 241 AVAILABILITY AND CONSULTATION OF THE PREPARATORY DOCUMENTS FOR THE VIRIDIEN COMBINED GENERAL MEETING OF WEDNESDAY, APRIL 30, 2025 Paris, France – April 9, 2025 The Combined General Meeting of Viridien (the “Company”) will be held on Wednesday, April 30, 2025 at 10.30 a.m. at Cloud Business Center, 10 bis rue du Quatre Septembre, 75002 Paris, ...

Core Insights - Viridien has been awarded a contract by Groupement Hassi Bir Rekaiz to reimage two legacy 3D seismic data sets totaling 2,400 sq km in the Hassi Bir Rekaiz concession in Eastern Algeria [1][2] - The project will last for 13 months and aims to enhance seismic data quality using advanced technology for better reservoir insights and increased drilling success [2][3] - The contract reflects client confidence in Viridien's expertise and technological advancements in the growing Algerian market [3] Company Overview - Viridien is a technology-driven company focused on Earth data, aiming to resolve complex challenges in natural resources, energy transition, and infrastructure [4] - The company employs approximately 3,500 people globally and is listed on Euronext Paris SA under the ticker VIRI [4]

PART I [Business](index=6&type=section&id=Item%201.%20Business) Dogwood Therapeutics is a pre-revenue biopharmaceutical company developing pain and fatigue medicines, featuring Halneuron® and antiviral therapies - The company is a pre-revenue, development-stage biopharmaceutical firm focusing on pain and fatigue-related disorders[24](index=24&type=chunk) - The company's pipeline has two main pillars: Nav 1.7 modulation for pain (Halneuron®) and combination antiviral therapies for herpes virus-mediated illnesses (IMC-1, IMC-2)[25](index=25&type=chunk) - On October 7, 2024, the company acquired 100% of Pharmagesic (Holdings) Inc. through a Share Exchange Agreement, which included its subsidiaries and the Halneuron® program[179](index=179&type=chunk) [Nav1.7 Non-Opioid Analgesic Program (Halneuron®)](index=6&type=section&id=Nav1.7%20Non-Opioid%20Analgesic%20Program%20%28Halneuron%C2%AE%29) Halneuron®, a late-stage clinical candidate for chemotherapy-induced neuropathic pain (CINP), initiated Phase 2b trials in Q1 2025 - Halneuron®, the lead product candidate, is in late-stage clinical development for Chemotherapy-Induced Neuropathic Pain (CINP). Its active ingredient is highly purified Tetrodotoxin (TTX)[26](index=26&type=chunk) - The global CINP drug market is estimated at approximately **$1.5 billion** annually, with the broader cancer-related pain market reaching about **$5 billion**. Halneuron® has the potential to be the first FDA-approved treatment for CINP[36](index=36&type=chunk) - The HALT-CINP-203 Phase 2b clinical trial commenced in Q1 2025 to assess the efficacy and safety of Halneuron® in 200 patients with moderate to severe CINP. An interim analysis is planned for Q4 2025[43](index=43&type=chunk) [Antiviral Program (IMC-1 and IMC-2)](index=10&type=section&id=Antiviral%20Program%20%28IMC-1%20and%20IMC-2%29) The antiviral program focuses on IMC-1 and IMC-2, fixed-dose combinations for Fibromyalgia and Long-COVID - IMC-1 and IMC-2 are fixed-dose combinations of an anti-herpes antiviral and celecoxib, designed to treat diseases like Fibromyalgia (FM) and Long-COVID (LC) by suppressing herpesvirus activation[50](index=50&type=chunk) - The FORTRESS Phase 2b study for IMC-1 in FM did not meet its primary endpoint overall (p=0.302). However, a post-hoc analysis of a specific patient cohort enrolled later in the trial showed statistically significant improvement in pain (p=0.03)[64](index=64&type=chunk)[65](index=65&type=chunk) - The FDA has agreed to a Phase 3 program for IMC-1 in FM, which will include two pivotal trials. The company is currently exploring partnership opportunities to advance this program[68](index=68&type=chunk) - An exploratory study of IMC-2 in Long-COVID patients showed clinically meaningful improvements in fatigue and sleep disruption, though it was not statistically significant due to the small sample size. The company is seeking external financing to continue its development[84](index=84&type=chunk) [Intellectual Property](index=18&type=section&id=Intellectual%20Property) The company's IP strategy focuses on patent rights for Halneuron® and antiviral programs, with exclusivity extending to 2045 and 2033 - The Halneuron® patent portfolio includes **7 issued families** in the U.S. and abroad, with patents related to manufacturing, formulation, and use. Exclusivity for issued patents expires between **2027-2030**, with pending patents potentially extending to **2042 and 2045**[96](index=96&type=chunk) - The antiviral portfolio includes **21 issued patents** in the U.S. and abroad for IMC-1, including three Composition of Matter patents. Exclusivity for all these patents extends to **2033**[102](index=102&type=chunk) [Government Regulation](index=22&type=section&id=Government%20Regulation) The company's operations are subject to extensive FDA and global regulations, with fixed-dose combination products eligible for the 505(b)(2) pathway - The company's products are subject to extensive regulation by the FDA and other authorities, covering all stages from development to post-marketing[117](index=117&type=chunk)[119](index=119&type=chunk) - The company's fixed-dose combination products, IMC-1 and IMC-2, are eligible for the FDA's 505(b)(2) approval pathway, allowing reliance on existing data for their individual approved components (famciclovir, celecoxib, valacyclovir)[85](index=85&type=chunk)[161](index=161&type=chunk) - The FDA has granted Fast Track designation for IMC-1 for the treatment of Fibromyalgia, a program intended to expedite the development and review of drugs for serious conditions with unmet medical needs[134](index=134&type=chunk)[136](index=136&type=chunk) [Risk Factors](index=35&type=section&id=Item%201A.%20Risk%20Factors) The company faces significant risks including going concern doubt, high development uncertainty for clinical-stage products, and reliance on third parties - The company has recurring losses from operations, raising substantial doubt about its ability to continue as a going concern. The independent auditor's report includes an explanatory paragraph regarding this uncertainty[189](index=189&type=chunk)[190](index=190&type=chunk) - The company is heavily dependent on the success of its three main product candidates: Halneuron®, IMC-1, and IMC-2, all of which are still in clinical development and face uncertain regulatory approval and commercialization[206](index=206&type=chunk) - The company relies on third-party contract manufacturing organizations (CMOs) for the production of its clinical supplies and intends to do so for commercial supply, which poses risks related to quality control, compliance, and supply chain stability[278](index=278&type=chunk) - The company faces potential early generic competition for its products, as the active ingredients in its candidates are already available. This could impact market exclusivity and profitability[250](index=250&type=chunk)[252](index=252&type=chunk) [Cybersecurity](index=78&type=section&id=Item%201C.%20Cybersecurity) The company maintains a cyber-risk management program overseen by the Audit Committee, focusing on social engineering threats - The company's cybersecurity program is integrated into its overall enterprise risk management and is overseen by the Audit Committee[393](index=393&type=chunk)[395](index=395&type=chunk) - The most significant identified cybersecurity risk is social engineering, and all employees receive training twice a year to mitigate this threat[396](index=396&type=chunk) - As a virtual company, Dogwood relies on the internal controls of its third-party vendors for data protection and reviews their SOC reports annually[398](index=398&type=chunk) [Properties](index=79&type=section&id=Item%202.%20Properties) The company operates virtually in the U.S. and leases office space for its Canadian operations in British Columbia - The company does not own or lease real property in the U.S. and operates virtually. It leases office space in Vancouver, B.C., Canada[401](index=401&type=chunk) [Legal Proceedings](index=79&type=section&id=Item%203.%20Legal%20Proceedings) The company is not currently party to any pending material litigation, though claims may arise in the ordinary course of business - As of the report date, the company does not have any pending litigation that is considered material[402](index=402&type=chunk) PART II [Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=79&type=section&id=Item%205.%20Market%20for%20Registrant%27s%20Common%20Equity%2C%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities) The company's common stock trades on Nasdaq under 'DWTX', faced compliance issues, and does not pay cash dividends on common stock - The company's stock symbol changed from **'VIRI' to 'DWTX'** on October 9, 2024, following the business combination and name change[404](index=404&type=chunk) - The company received a notice from Nasdaq in November 2024 for falling below the minimum stockholders' equity requirement of **$2.5 million**. It was granted an extension until May 14, 2025, which it estimates it achieved as of March 14, 2025[408](index=408&type=chunk) - The company has never paid cash dividends on its common stock and does not plan to. However, Series A Preferred Stock accrues a **5.0%** annual payment-in-kind dividend[410](index=410&type=chunk)[411](index=411&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=81&type=section&id=Item%207.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) The pre-revenue company reported a **$12.3 million** net loss in 2024, secured **$19.5 million** in debt and **$4.25 million** from an offering, with cash funding operations through Q1 2026 - The company is pre-revenue and its operations are funded through equity and debt financings[416](index=416&type=chunk)[461](index=461&type=chunk) - In October 2024, the company entered into a **$19.5 million** loan agreement with Conjoint Inc., an affiliate of CKLS. This debt was subsequently converted into Series A-1 Preferred Stock in March 2025[422](index=422&type=chunk)[430](index=430&type=chunk) - In March 2025, the company raised approximately **$4.25 million** in net proceeds from a registered direct offering of common stock[431](index=431&type=chunk) - Management anticipates that cash on hand as of December 31, 2024, plus proceeds from recent financing activities, will fund operations through the **first quarter of 2026**. Additional financing will be required thereafter[467](index=467&type=chunk) [Results of Operations](index=87&type=section&id=Results%20of%20Operations) For 2024, the company reported a **$12.3 million** net loss, up from **$5.3 million** in 2023, primarily due to **$4.9 million** in non-recurring transaction costs Comparison of Operating Expenses and Other Income (Expense) | | Year Ended December 31, (in USD) | | | :--- | :--- | :--- | | | **2024** | **2023** | | **Operating expenses:** | | | | Research and development | $ 3,530,913 | $ 1,728,078 | | General and administrative | 8,696,335 | 3,718,841 | | **Total operating expenses** | **$ 12,227,248** | **$ 5,446,919** | | **Other (expense) income, net** | $ (122,979) | $ 150,904 | | **Loss before income taxes** | **$ (12,350,227)** | **$ (5,296,015)** | - Research and development expenses increased by **$1.8 million** in 2024, mainly due to a **$1.0 million** increase in clinical trial expenses and a **$0.4 million** increase in drug development and manufacturing costs[457](index=457&type=chunk) - General and administrative expenses increased by **$5.0 million** in 2024, primarily due to **$4.9 million** in nonrecurring transaction costs related to the Combination[458](index=458&type=chunk) [Liquidity and Capital Resources](index=88&type=section&id=Liquidity%20and%20Capital%20Resources) As of December 31, 2024, the company had **$14.8 million** in cash, with financing activities providing **$16.7 million** in 2024, but additional capital is needed Summary of Cash Flows | | Years Ended December 31, (in USD) | | | :--- | :--- | :--- | | | **2024** | **2023** | | **Net cash used in operating activities** | $ (8,790,805) | $ (4,870,489) | | **Net cash provided by investing activities** | $ 3,761,936 | $ — | | **Net cash provided by financing activities** | $ 16,704,464 | $ 1,156,443 | - As of December 31, 2024, the company's principal source of liquidity was cash totaling **$14.8 million**[461](index=461&type=chunk) - The company will need to secure additional financing to fund operations beyond the **first quarter of 2026**, and substantial doubt exists about its ability to continue as a going concern[467](index=467&type=chunk) [Financial Statements and Supplementary Data](index=91&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data) Consolidated financial statements for 2024 and 2023 are presented, with the auditor's report expressing substantial doubt about going concern due to recurring losses - The independent auditor's report expresses substantial doubt about the Company's ability to continue as a going concern due to its accumulated deficit and lack of revenue[486](index=486&type=chunk) Consolidated Balance Sheet Highlights (as of Dec 31) | | 2024 (in USD) | 2023 (in USD) | | :--- | :--- | :--- | | **Total Assets** | $94,308,246 | $4,165,442 | | Goodwill | $11,812,476 | $— | | Intangible assets | $65,710,527 | $— | | **Total Liabilities** | $30,027,223 | $358,548 | | Debt with related party, net | $15,381,077 | $— | | **Total stockholders' (deficit) equity** | $(10,124,339) | $3,806,894 | Consolidated Statement of Operations Highlights (Year Ended Dec 31) | | 2024 (in USD) | 2023 (in USD) | | :--- | :--- | :--- | | **Total operating expenses** | $12,227,248 | $5,446,919 | | **Net loss** | $(12,349,724) | $(5,296,015) | | **Net loss per common share** | $(12.52) | $(7.05) | [Controls and Procedures](index=119&type=section&id=Item%209A.%20Controls%20and%20Procedures) Management concluded that disclosure controls and internal control over financial reporting were effective as of December 31, 2024 - Management concluded that disclosure controls and procedures were effective as of the end of the period covered by the report[621](index=621&type=chunk) - Management concluded that internal control over financial reporting was effective as of December 31, 2024, based on the COSO 2013 framework[623](index=623&type=chunk) - The company is currently integrating the legacy Pharmagesic business into its system of internal control, which may result in future changes[625](index=625&type=chunk) PART III [Directors, Executive Officers, Corporate Governance, Compensation, and Accountant Fees](index=120&type=section&id=Items%2010-14) Information for Items 10-14 regarding directors, executive officers, corporate governance, compensation, and accountant fees is incorporated by reference - Information for Items 10, 11, 12, 13, and 14 is incorporated by reference from the forthcoming 2025 definitive proxy statement[628](index=628&type=chunk)[630](index=630&type=chunk)[631](index=631&type=chunk)[632](index=632&type=chunk)[633](index=633&type=chunk) PART IV [Exhibits and Financial Statement Schedules](index=120&type=section&id=Item%2015.%20Exhibits%20and%20Financial%20Statement%20Schedules) This section lists all financial statements and exhibits filed with the Annual Report, with financial statement schedules omitted - This section provides an index of all financial statements and exhibits filed with the Annual Report[635](index=635&type=chunk)[636](index=636&type=chunk)[637](index=637&type=chunk)

Financial Performance - Net loss attributable to common stockholders for Q4 2024 was $8.2 million, or $6.29 per share, compared to a net loss of $1.1 million, or $1.43 per share, in Q4 2023[10]. - For the full year 2024, net loss attributable to common stockholders was $12.9 million, or $12.52 per share, compared to a net loss of $5.3 million, or $7.05 per share, in 2023[14]. Expenses - Research and development expenses for Q4 2024 were $2.3 million, a 567% increase from $0.3 million in Q4 2023[8]. - General and administrative expenses for Q4 2024 were $5.2 million, up 575% from $0.8 million in Q4 2023, primarily due to nonrecurring transaction costs[9]. Capital and Funding - The company converted $19.5 million in debt to equity, significantly improving its balance sheet[5]. - A recent capital raise of $4.8 million, combined with existing cash, provides operational runway through Q1 2026[5]. - As of December 31, 2024, Dogwood Therapeutics had cash totaling $14.8 million, sufficient to fund operations through Q1 2026[14]. Assets and Liabilities - Total assets increased to $94.3 million as of December 31, 2024, compared to $4.2 million in 2023[23]. - Total liabilities rose to $30.0 million as of December 31, 2024, compared to $0.4 million in 2023[23]. Clinical Development - Dogwood Therapeutics commenced dosing in its Halneuron® Phase 2b CINP program, with interim data expected in Q4 2025[5].